A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT04699630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Study identification
- NCT ID
- NCT04699630
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 121 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2021 (Actual)
- Primary completion
- Apr 9, 2025 (Actual)
- Completion
- Apr 9, 2025 (Actual)
- Last update posted
- May 22, 2026
2021 – 2025
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| City of Hope | Duarte | California | 91010 | — |
| Florida Cancer Specialists-South | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists-North | St. Petersburg | Florida | 33705 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Rutgers-Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04699630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04699630 live on ClinicalTrials.gov.